Another study described the use of several non-invasive biomarkers concomitantly (PSA together with androgen receptor CAG analysis and promoter methylation analysis) increasing predictive power of the prostate cancer and allowing its discrimination from benign prostate hyperplasia in 70–80% of cases [93]. The gene discussed is KLK3; the disease is Familial prostate cancer.